AVALON: Another large real-world study comparing ambulatory cardiac monitoring services

Click here to see the study
Support
Support
Search

Helping care teams identify heart rhythm conditions earlier in the care journey

Value-based care organizations are redefining proactive population health. iRhythm’s cardiac arrhythmia detection programs support the identification of previously undiagnosed heart rhythm conditions across your population - enabling more informed care decisions and helping align with quality and cost management goals.

Afro haired black woman sitting on a couch, surrounded by a bookshelf. She holds a mobile phone, looking thoughtful. Mature black woman enjoying her leisure time at home.
Empowering the leaders driving value-based care forward

Supporting the full spectrum of value-based health leaders; including Value-Based Primary Care, Accountable Care Organizations (ACOs), Clinically Integrated Networks (CINs), Health Assessment Organizations, Healthcare Enablers, and Payers/Payviders.

The challenge

By 2050, cardiovascular-related factors alone will cost the U.S. over $1.3 trillion annually, more than triple today’s burden. Without early detection and proactive management, the cost of inaction could exceed $2.2 trillion each year, underscoring the urgent need for scalable prevention strategies.2

Talk to our team

Why it matters

Undiagnosed arrhythmias carry silent but significant risks:

Nearly 1 in 4 people with atrial fibrillation remain undiagnosed over a two-year period.3
Atrial fibrillation accounts for 25% of ischemic strokes in older adults.2
People with AFib have a 5X risk of heart failure, a condition projected to reach $70 billion by 2030.5,6
Healthcare, elderly woman with nurse with breakfast at her home and at the table in living room. Support or communication, caregiver and conversation with medical person with senior or old female

The iRhythm impact

Transforming the way cardiac arrhythmias are diagnosed.

 

Zio® long-term continuous monitoring (LTCM) helps transform population health programs by enabling earlier arrhythmia detection, which may support improved outcomes while reducing costly hospital utilization.

Lowest average emergency department length of stay and inpatient utilization compared to AEM, MCT, and Holter monitors.7-9

On average, 180 fewer ED visits, 80 fewer hospitalizations, and 920 fewer outpatient visits per 1,000 patients compared to Holter monitoring.7-9

Zio® LTCM service was associated with the lowest likelihood of a cardiovascular event at one year outperforming all other modalities, including Holter, AEM, and non-iRhythm LTCM services.9-11

The power of partnership

The iRhythm service delivers high-impact cardiac monitoring solutions, while Heartbeat Health’s12 virtual cardiology practice provides comprehensive diagnostics and care planning. From advanced arrhythmia detection to virtual cardiology expertise, our teams empower you to enhance care, streamline workflows, and drive results.

Scale and expertise

With over 12 million patient reports processed and 2 billion hours of curated heartbeat data, iRhythm delivers unmatched clinical insight and reliability across diverse care models.

Real world clinical and economic studies show Zio LTCM is associated with:

Camelot study highlights

CAMELOT is the first and largest real-world evidence study of diagnostic-naive Medicare beneficiaries managed with external cardiac monitoring services.15
Explore the data

Avalon study highlights

The largest real-world study of ambulatory cardiac monitoring (ACM) in a commercially insured population (n=428,707), offering a comprehensive view of long-term continuous monitoring in everyday care.10
Explore the data
A photo of a person holding a tablet showing a Zio report.

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions.

Read more
Clinical Article
Russo P, Coetzer H, Hendrickson EM, Boyle K, Wright B., Am J Manag Care. 2025
Assessment of Variation in Ambulatory Cardiac Monitoring (AVALON) Study
A retrospective study of analyzing commercially insured patient populations, examined how monitoring strategy influenced arrhythmia diagnosis, clinical outcomes, and healthcare resource utilization.
Read more
Clinical Article
Reynolds et al, American Heart Journal, 2023.
Comparative Effectiveness of ACM Strategies (CAMELOT Study)
A retrospective study of variations in ACM strategies, clinical outcomes and health care costs in diagnostic-naïve patients.
Read more
Clinical Article
Barrett et al., American Journal of Medicine, 2014.
Comparison of 24-Hour Holter Monitoring Versus 14-Days
A prospective study comparing the detection of arrhythmia events over total wear time with the Zio device to Holter monitoring.
Read more

Ready to reduce risk and reimagine population health outcomes?

Connect with our Value-Based Care Team.

  1. ⁠American Heart Association. Cardiovascular Disease CVD Fact Sheet. 2025. Available at: https://newsroom.heart.org/facts/cardiovascular-disease-cvd
  2. American Heart Association. Forecasting the Economic Burden of Cardiovascular Disease 
    and Stroke in the United States Through 2050. Circulation. 2023;147:eXXX eXXX. Available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001122
  3. Turakhia et al. Contemporary prevalence estimates of undiagnosed and diagnosed 
    atrial fibrillation in the United States. Clinical Cardiology. 2023;46(5):484 493. doi:https://doi.org/10.1002/clc.23983
  4. Alkhouli et al. Burden of atrial fibrillation associated ischemic stroke in the United States. JACC: Clinical Electrophysiology. 
    2018;4(5):618 625. doi:10.1016/j.jacep.2018.02.021 
  5. Joglar et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee 
    on Clinical Practice Guidelines. Circulation. 2024;149:e1 e156. doi: 10.1161/CIR.0000000000001193 
  6. Heidenreich et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. 
    Circulation: Heart Failure. 2013;6(3):606 619. doi:https://doi.org/10.1161/hhf.0b013e318291329a 
  7. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 
    2024;269:2534. https://doi.org/10.1016/j.ahj.2023.12.002 
  8. The study is based on the previous generation Zio XT device data. The devices used in the Zio LTCM monitoring service are deemed substantially equivalent. Additional data on file. 
  9. Zio LTCM service refers to Zio XT and Zio monitor service. 
  10. Russo et al. Assessment of variation in ambulatory cardiac monitoring among commercially insured patients. Am J Manag Care. Published online August 13, 2025. doi:10.37765/
    ajmc.2026.89782 
  11. CV events are defined by the study protocol. 
  12. iRhythm performs ambulatory cardiac monitoring services. Heartbeat Health is a third-party that provides ordering, diagnostic and interpretation services. 
  13. Data on file. iRhythm Technologies. 2026. 
  14. Data on file. iRhythm Technologies, 2024. 
  15. Data on file. iRhythm Technologies, 2023.

WEB0015.03

Contact Us